SynthesisPloS one2014

Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.

Xiao-song Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.